Wave Life Sciences (NASDAQ:WVE) shares soared 73% Wednesday afternoon after the company announced positive proof-of-mechanism data from its Phase 1b/2a RestoraAATion-2 study for its RNA editing ...
Wave Life Sciences said today its alpha-1 antitrypsin deficiency (AATD) candidate WVE-006 succeeded in the first-ever clinical demonstration of RNA editing in humans by achieving positive proof-of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback